-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Preclinical and clinical data indicate that fibroblast growth factor 21 (FGF21) has the potential to fight fibrosis, improve metabolic status, and treat non-alcoholic steatohepatitis (NASH)
Recently, a research article was published in the top medical journal Nature Medicine.
The study is a randomized, placebo-controlled study (ClinicalTrials.
manage
Signs of liver damage
For the entire analysis set, in the 28 mg, 50 mg, and 70 mg efruxifermin treatment groups, the least squares mean absolute change in HFF from baseline (unilateral 97.
It can be seen that efruxifermin treatment significantly reduces the HFF of patients with F1-F3 stage NASH, and its safety is acceptable
Efruxifermin treatment significantly reduces HFF in patients with stage F1-F3 NASH, and its safety is acceptable
Original source:
Original source:Stephen A.
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
in this message